|Number of pages||3|
|Journal||JACC. Cardiovascular imaging|
|Publication status||Published - 1 Apr 2022|
Access to Document
Other files and links
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. / Honda, Satoshi; Puri, Rishi; Anderson, Todd et al.In: JACC. Cardiovascular imaging, Vol. 15, No. 4, 01.04.2022, p. 709-711.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
AU - Honda, Satoshi
AU - Puri, Rishi
AU - Anderson, Todd
AU - Kastelein, John J. P.
AU - Brennan, Danielle M.
AU - Kassahun, Helina
AU - Somaratne, Ransi
AU - Wasserman, Scott M.
AU - Nissen, Steve E.
AU - Nicholls, Stephen J.
N1 - Funding Information: Dr Puri has received consulting fees from Cerenis, Sanofi-Aventis and Amgen Inc. Dr Anderson has received honoraria (<$5,000) for speaking from Amgen Inc, Bayer, and Sanofi; and was the local principal investigator on clinical research studies for Amgen Inc and Dalcor. Dr Kastelein has received personal consulting fees from Sanofi, Affiris, Akarna Therapeutics, Amgen Inc, CSL Behring, Regeneron, Staten Biotech, Madrigal, The Medicines Company, Kowa, Lilly, Esperion, Gemphire, Ionis Pharmaceuticals, and Akcea Pharmaceuticals. Dr Kassahun is an employee and stockholder of Amgen Inc. Dr Somaratne was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on at least one patent application owned by Amgen relating to evolocumab. Dr Wasserman was an employee of Amgen Inc; owns stock in Amgen Inc; and was an inventor on multiple patents and patent applications owned by Amgen Inc relating to evolocumab during the conduct of the study. Dr Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen Inc, Cerenis, Eli Lilly, Esperion, Pfizer, The Medicines Company, Takeda, and Orexigen, he is involved in these clinical trials, but receives no personal remuneration for his participation; and consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2022/4/1
Y1 - 2022/4/1
UR - http://www.scopus.com/inward/record.url?scp=85127193329&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jcmg.2021.11.014
DO - https://doi.org/10.1016/j.jcmg.2021.11.014
M3 - Comment/Letter to the editor
C2 - 34922870
VL - 15
SP - 709
EP - 711
JO - JACC Cardiovascular Imaging
JF - JACC Cardiovascular Imaging
SN - 1936-878X
IS - 4